ACM
GLUE icon

Aisling Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Aisling Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.6M Hold
1,555,664
– – 7.98% 2
2026
Q1 		$25.6M Buy
1,555,664
+83,333
+6% +$1.59M 5.37% 3
2025
Q4 		$23.1M Hold
1,472,331
– – 4.82% 3
2025
Q3 		$10.9M Hold
1,472,331
– – 2.39% 5
2025
Q2 		$6.64M Hold
1,472,331
– – 1.85% 4
2025
Q1 		$6.83M Hold
1,472,331
– – 2.37% 5
2024
Q4 		$10.2M Hold
1,472,331
– – 3.63% 4
2024
Q3 		$7.8M Hold
1,472,331
– – 2.99% 6
2024
Q2 		$5.51M Hold
1,472,331
– – 2.38% 7
2024
Q1 		$10.4M Hold
1,472,331
– – 3.51% 6
2023
Q4 		$8.32M Hold
1,472,331
– – 2.48% 6
2023
Q3 		$7.05M Hold
1,472,331
– – 2.91% 6
2023
Q2 		$10.1M Hold
1,472,331
– – 4.94% 5
2023
Q1 		$11.5M Hold
1,472,331
– – 5.52% 5
2022
Q4 		$11.2M Hold
1,472,331
– – 7.4% 4
2022
Q3 		$12M Hold
1,472,331
– – 7.99% 4
2022
Q2 		$14.2M Hold
1,472,331
– – 10.16% 3
2022
Q1 		$20.6M Hold
1,472,331
– – 11.14% 2
2021
Q4 		$30.1M Hold
1,472,331
– – 10.61% 2
2021
Q3 		$32.8M Hold
1,472,331
– – 6.54% 2
2021
Q2 		$33.4M Buy
+1,472,331
New +$30M 5.35% 3

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Aisling Capital Management's GLUE Position: Q2 2026 in Review

Aisling Capital Management held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 1,555,664 shares worth $37.6M. The position accounts for 7.98% of the portfolio, ranked #2.

Aisling Capital Management first reported a position in GLUE in Q2 2021 and has held it in 21 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Aisling Capital Management held 1,555,664 shares of Monte Rosa Therapeutics worth $37.6M as of Q2 2026.
  • Aisling Capital Management left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
  • Monte Rosa Therapeutics made up 7.98% of Aisling Capital Management's portfolio in Q2 2026, its #2 holding.
  • Aisling Capital Management first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Aisling Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.